Pleural Effusion in Dasatinib-Treated Patients With Chronic Myeloid Leukemia in Chronic Phase: Identification and Management

Jorge E. Cortes, Carlos A. Jimenez, Michael J. Mauro, Alex Geyer, Javier Pinilla-Ibarz, B. Douglas Smith

Research output: Contribution to journalReview article

17 Scopus citations

Abstract

Dasatinib has demonstrated durable clinical responses in patients, both as first-line and subsequent lines of therapy. Dasatinib use can result in pleural effusion in some patients, occurring any time during treatment and commonly characterized as mild to moderate in severity. Early identification of symptoms is essential in the proper management of pleural effusion. Prompt confirmation of diagnosis and management of pleural effusion can minimize morbidity and maximize the ability to preserve long-term clinical benefits with dasatinib. Here, we provide guidance on early identification and management of dasatinib-related pleural effusion.

Original languageEnglish (US)
Pages (from-to)78-82
Number of pages5
JournalClinical Lymphoma, Myeloma and Leukemia
Volume17
Issue number2
DOIs
StatePublished - Feb 1 2017
Externally publishedYes

Keywords

  • Adverse events
  • Algorithms
  • BCR-ABL1
  • Fluid retention
  • Tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Pleural Effusion in Dasatinib-Treated Patients With Chronic Myeloid Leukemia in Chronic Phase: Identification and Management'. Together they form a unique fingerprint.

  • Cite this